A U.S. House of Representatives investigative panel said it plans to hold a 2016 hearing on skyrocketing drug costs, a move that comes at a time when Valeant Pharmaceuticals International is facing increased scrutiny into its pricing practices. A spokeswoman for the U.S. House Committee on Oversight & Government Reform said on Monday the panel is conducting a thorough investigation into drug pricing and has reached out to drug companies to gather information. Earlier this month, the U.S.